Skip to main content
. 2004 Oct 14;32(18):5546–5552. doi: 10.1093/nar/gkh896

Figure 3.

Figure 3

Binding of active p53 protein to the 20 bp duplex containing CDRE (see Figure 2B for its sequence). The duplex was unplatinated (lane 1), globally modified by cisplatin (lanes 2–4) or BBR3464 (lanes 5–7). Gel-mobility retardation assay was performed in the presence of the unplatinated 2513 bp nonspecific competitor (PvuII fragment of pPMG1 lacking CDRE) in 5% native polyacrylamide gel; concentrations of the oligonucleotide duplex and 2513 bp fragment were 1.6 and 10 μg/ml (1.26 × 10−7 and 6 × 10−9 M), respectively and concentration of p53 was 3.9 × 10−8 M. rb values: 0 (lane 1); 0.0125 (lanes 2 and 5); 0.025 (lanes 3 and 6); 0.05 (lanes 4 and 7). The oligonucleotide duplex was radioactively labeled at the 5′-end of the top strand. For other details, see the experimental part. (A) Autoradiogram. (B) The plot of the amount of the oligonucleotide duplex in the complex with p53 protein on the amount of the platinum complex bound per one molecule of the duplex. Cisplatin, filled squares; BBR3464, empty squares.